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Binding of somatostatin-14 to rat liver plasma mem- 
branes was characterized with lzs-labeled[tyr"l 
somatostatin-14. Binding at 24" C reached a plateau 
at SO min and was reversible by synthetic 
somatostatin-14. Scatchard analysis revealed a single 
class of binding sites (affinity constant = 2.4 f 0.2 
nmol/L, binding capacity = 148 2 0.02 fmoUmg pro- 
tein). Specificity for somatostatin-14 was demon- 
strated by the inhibition of 1asI-[tyr111somatostatin-14 
binding by biologically active somatostatin analogs but 
not by a biologically inactive somatostatin analog or 
unrelated peptides. The radioiodinated binding site 
complex could be cross-linked with disuccinimidyl 
suberate. Analysis by sodium dodecyl sulfate- 
polyacrylamide gel electrophoresis and gel autoradiog- 
raphy revealed a 70,000-Da band. Dithiothreitol, a re- 
ducing reagent, did not alter the mobility of the band, 
and the band mould be abolished in the presence of 10 
pmol/L synthetic somatostatin- 14. Covalently cross- 
linked, iodinated binding protein complexes could be 
solubilized by the nonreducing detergents Zwittergent 
3-12 and 3-([3-cholamidopropyl] diethylammoni0)-l- 
propanesulfonic acid (CHAF'S). Solubilized complex 
bound to wheat-germ agglutinin-agarose columns and 
waa eluted by N, N', N"-triacetylchitotrioee. Binding to 
wheat-germ agglutinin agarose columns was lost after 
pmtreatment with endo-B-N-acetylglucosaminidase F. 
Binding studies with liver plasma membranes, lsSI- 
labeled[tyrasine11]somatostatin-14 and guanine nucle- 
otides showed inhibition of binding in the presence of 
guanine nucleotides. 
These results indicate that the purified rat liver 
plasma membranes contain a specific binding protein 
for somatostatin-14, the binding protein appears to be 
glycoqdated and somatostatin-14 binding to rat liver 
plasma membranes may be regulated by G proteins. 
(HEPMW..OCY 1992; 16433-439.) 
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Somatostatin-14 (SS-  14) was first discovered as an 
inhibitor of growth hormone secretion. It has since been 
shown to regulate brain and gut function by paracrine 
mechanisms (1, 2). SS-14 inhibits adenylate cyclase 
activity in isolated rat hepatocytes and liver (3,4). It also 
inhibits glycogenolysis and very low density lipoprotein 
production in the isolated, perfused rat liver (5, 6). 
Taken together, the data suggest the existence of a direct 
effect of SS-14 on the liver, possibly receptor-mediated 
(7). SS-14 binding to liver has been reported previously 
(8). One study using an SS-14 analog showed binding to 
the liver cell plasma membrane (9), whereas other 
studies using a dynamic dilution technique demon- 
strated 9.8% binding that could not be displaced by 
synthetic SS-14 (10). In this report, we identified and 
characterized SS-14 binding sites on rat liver plasma 
membranes using a conventional direct binding assay 
and biochemical characterization with a variety of 
standard techniques. 
MATERIALS AND METHODS 
Chemicals. All protease inhibitors, sugars, agarose, wheat 
germ agglutinin WGA) and endo- P-N-acetylglucosaminidase 
F (endo F) were obtained from Sigma Chemical Co. (St. Louis, 
MO). SS-14, [tyr"]SS-14 and all other peptides were obtained 
from Peninsula Laboratories (Belmont, CA). Disuccimidyl 
suberate (DSS) and other cross-linking reagents were obtained 
from Pierce Chemical (Rockford, IL). All reagents used in 
SDS-PAGE were of electrophoresis grade and were obtained 
from Bio-Rad Laboratories (Richmond, CAI or from 
Boehringer-Mannheim (Indianapolis, IN). Radioactive sodium 
iodide for the radioiodination of [tyr1'ISS-14 was obtained 
from Amersham (Arlington Heights, IL). 5'-Nucleotidase, 
aklaline phosphatase and total protein were assayed with 
commercial kits obtained from Sigma Chemical Co. 
leolution of Highly PuriJied Rat Liver Plaema Membranes. 
Rat liver plasma membranes were prepared from the livers of 
adult male Sprague-Dawley rats (250 to 275 gm) (11). Rat liver 
was homogenized with 10 strokes in a Dounce tissue homog- 
enizer (Sigma Chemical Co.) containing 50 ml ice-cold buffer 
(0.5 mmol/L CaCl,, 1 mmol/L NaHCO,, 2 p,mol/L leupeptin, 2 
&morn pepstatin, 1 &mol/L PMSF and 0.1 m g / d  bacitracin at 
pH 7.5). After three low-speed centrifugations (2,500 rpm), the 
crude preparation was pooled in a 50-ml ultracentrifuge tube 
and spun through a discontinuous sucrose density gradient for 
2 hr at 25,000 rpm and at 4" C. The liver plasma membranes 
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layered at the interface of 37% and 41% sucrose. The plasma 
membrane fraction collected from the interface was then 
stored at - 70" C. Two separate membrane enzyme analyses- 
5'-nucleotidase and alkaline phosphatase- were performed in 
the crude homogenate and the final membrane preparation 
(11). Membranes were accepted as pure, with at least a 20-fold 
increase in enzyme activity per milligram wet weight. Mem- 
branes were used immediately or suspended in 50 mmol/L 
HEPES buffer (pH 7.4); aliquots were kept at -70" C until 
ready for use. 
Binding Assay. Radiolabeling of the SS-14 analog 
[tyr1'1SS-14 was performed as described previously with 
chloramine-T (12). [tyr"]SS-14 (2.4 nmol), lz5NaI (0.5 mCi) 
and chloramine-T were incubated in 0.04 mom sodium 
phosphate buffer in a final reaction volume of 100 ~ 1 .  The 
specific activity of the tracer was -1,000 Ci/mmol. The 
radioligand was purified by reverse-phase HPLC on a FBon- 
dapak C18 column (0.39 x 30 cm; Waters Associates, Milford, 
MA). Elution buffer A was 2% trifluoroacetic acid and buffer B 
was 2% trifluoroacetic acid with 50% acetonitrile. The column 
was eluted at a flow rate of 1 mVmin at room temperature with 
a protocol of 5 rnin at 0% buffer B, 17.5 min gradient of 0% to 
70% buffer B, 10 min at 70% buffer B and 70% to 0% buffer B 
(13). 
Binding of 1251-[tyr1']SS-14 (50 pmol/L) to plasma mem- 
brane (20 pg/ml) was carried out in 0.5 ml of binding buffer 
(1 mmol/L NaHCO,, 0.5 mmoVL CaCl,, 2 pmol/L leupeptin, 
2 Fmol/L pepstatin, 1 mmol/L PMSF and 0.1 mg/ml bacitracin) 
and increasing concentrations of synthetic peptides or nucle- 
otides at pH 7.5 for 50 rnin at 24" C. When the incubation 
temperature was decreased to 4" C, no significant specific 
binding was seen, but a decrease in maximal binding at 37" C 
did appear. Membrane-bound 1251-[tyr11]SS-14 was separated 
by centrifugation at  10,000 g for 15 min at 4" C and washed 
with fresh binding buffer. Pellet radioactivity was monitored 
with a gamma counter. Binding to liver plasma membranes in 
the presence of 10 FmoVL SS-14 was considered nonspecific 
binding. The elution profile of the binding assay supernatant 
was obtained on a Sephadex G-50 Superfine (100 cm x 1 cm) 
chromatography column (LKB-Pharmacia, Piscataway, NJ) 
in 1 M glacial acetic acid as described (14). Stability of 
1251-[tyr"]SS-14 incubated for 50 min with membranes was 
92%-identical to stability of '261-[tyr11]SS-14 incubated in 
the absence of rat liver plasma membranes. 
M n i t y  Cross-Linking Protocol. Fifty micrograms of rat 
liver plasma membranes were incubated in 0.5 ml of binding 
buffer in the presence or absence of SS-14 with lZ5I- 
[tyr'']SS-14 (150 pmol/L) for 50 rnin at 24" C (15). In some 
experiments, we used 10 Fg membranes and '251-[tyr1'lSS-14 
(30 pmol/L). The mixture was centrifuged at 10,000 g for 15 
min at 4" C. The pellet was washed in 1.0 ml of ice-cold 
binding buffer and recentrifuged for 10 min at 10,000 g and 
4" C. Three heterobifunctional cross-linking reagents - N- 
hydroxysuccinimidyl4-azidobenzoate (HSAB), N-succinimidyl 
6-(azido-2'-nitrophenylamine) hexanoate (SAN-PAH) and 
N-(5-azido-2'-nitrobenzoyloxy)-succinimide (ANB-NOS) - 
were used. The heterobifunctional photoreactive cross-linking 
reagents were freshly dissolved in DMSO and added at  a 1 : 100 
dilution to a final concentration of 100 FmoVL to the 
resuspended pellet. Membrane suspensions were then trans- 
ferred to 16-mm Costar plates (Costar, Cambridge, MA) and 
exposed to UV light (275-W sunlamp) at a distance of 15 cm for 
15 rnin at 4" C. Ice-cold buffer containing 2 mmol/L EDTA was 
added, and membranes were pelleted. The homobifunctional 
cross-linking reagent DSS was dissolved in DMSO and added 
at  a 1 : 100 dilution to a final concentration of 1 mmol/L. The 
reaction was allowed to proceed for 20 min at  4" C and then 
quenched with 1 ml of 1 moVL ammonium acetate for 5 min at 
24" C (16). Pellets were washed with fresh buffer and then 
subjected to SDS-PAGE. 
SDS-PAGE. Affinity cross-linked membranes were solubi- 
lized in sample buffer (0.0625 m o m  Tris-HC1 [pH 6.81, 2.3% 
SDS [wt/vol], 10% glycerol [wt/vol], 5% P-mercaptoethanol 
[voVvoll and 5% bromphenol blue) by heating at 100" C for 
3 min. In some studies, 50 mmol/L dithiothreitol (DTT) was 
also added (17). Samples were subjected to electrophoresis in 
7.5% or 12% acrylamide and 1% SDS. The gels were fixed and 
dried; autoradiography was performed on dried gels by 
exposing them to Kodak X-Omat AR film (Eastman Kodak Co., 
Rochester, NY) with an enhancing screen at -70" C. A 
cross-linking efficiency of 1% to 2% was demonstrated by 
cutting the lanes on some dried gels into 0.5-cm blocks, then 
measuring each block for radioactivity in a gamma counter. 
Plasma Membrane Solubilization. Affinity-labeled mem- 
branes (1 mg/ml) were solubilized in 50 mmol/L Tris-HC1 
and 0.5 mmol/L benzamidine buffer containing 1% con- 
centrations of Zwittergent 3-12 (Calbiochem, La Jolla, CAI, 
3-([3-~holamidopropyl] dimethy1ammonio)-1-propanesulfonic 
acid (CHAPS), digitonin or Triton X-100. After gentle agitation 
for 30 min, the solubilized, affinity-labeled membranes were 
subjected to centrifugation at 100,OOOg for 60 rnin at 4" C (15). 
Supernatant radioactivity was counted in a gamma counter 
and expressed as counts per minute per milligram of protein. 
WGA Adsorption Chromatography. Ten milligrams of 
WGA-agarose beads in 1.0 ml of 1.0 moVL NaCl was packed 
into a 10 x 0.7 cm column and washed with 40 ml Tris-HCl(50 
mmol/L) containing 1% Zwittergent 3-12. Solubilized, affinity- 
labeled complexes were prepared as described above, and the 
supernatant was applied to the WGA-agarose column (Sigma 
Chemical Co.). The columns were washed with Ca' + buffer 
until they were free of detectable radioactivity. The column 
was then washed with 4 mmol/L N, N', N-triacetylchitotriose 
in buffer containing 1% Zwittergent 3-12. Two-milliliter 
fractions were collected, and radioactivity was assayed in a 
gamma counter (15). 
Hydrolysis of Glycoproteins. Hydrolysis of DSS (Pierce 
Chemical Co., Rockford, IL) cross-linked 1251-[tyr'1]SS-14 
binding protein complexes in a volume of 0.1 ml containing 1 
unit of endo F, 1% Zwittergent 3-12 and 20 mmol/L EDTA in 
0.25 mom sodium acetate was performed at 37" C for 1 hr (18, 
19). The resulting reaction product was pelleted by centrifu- 
gation at 2,500 rpm and subjected to SDS-PAGE; this was 
followed by silver staining and gel autoradiography. 
Statistical Analysis. For binding analysis, a multiple- 
variable curve-fitting program was developed after the method 
of Munson and Rodbard (20). Scatchard analysis was per- 
formed by plotting boundfree ligand vs. bound ligand. 
Ethical Considerations. The study protocol was approved 
by the University of Michigan Committee on Use and Care of 
Animals. 
RESULTS 
Characterization of SS-14 Binding to Liver Plasma 
Membranes. Specific binding of 1261-[tyr'11SS-14 to the 
rat liver plasma membrane preparation was time de- 
pendent. Steady-state binding to the liver plasma mem- 
branes reached a plateau by 50 min (Fig. 1A). At 
maximal specific binding, nonspecific binding was 30% 
to 40% of total binding. The addition of synthetic SS-14 
induced rapid dissociation of the bound radioactivity 
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FIG. 1. (A) Time course of binding of 1""I[tyr"]SS-14 to rat liver plasma membranes. Rat liver plasma membranes (20 FLglml) and 
'251-[tyr'11SS-14 (50 pmol/L) were incubated for increasing time intervals in the presence or absence of 10 pmol/L SS-14 (nonspecific) at 
24" C. Each point represents the mean of duplicate determinations of four experiments. Specific binding was obtained by subtracting nonspecific 
binding from total binding at  each point. (B) Dissociation of '251-[tyr'1]SS-14 from rat liver plasma membranes by unlabeled SS-14. Rat liver 
plasma membranes (20 Fg/ml) and '261-[tyr"lSS-14 (50 pmol/L) were incubated for 30 min, and 10 Fmol/L SS-14 was added. The incubation 
was continued for an additional 30 min. Each point represents the mean of duplicate determinations of three experiments. Specific binding was 
obtained by subtracting nonspecific binding from total binding at  each point. Ninety-two percent of the radioactivity in two supernatants 
examined eluted as a single peak in the same position as '2sI-ltyr1'lSS-14 as determined by chromatography on a Sephadex G-50 column (100 x 
1 an); this was identical to the stability of '251-[tyr111SS-14 in the absence of membranes. Error bars = S.E.M. 
TABLE 1. Relative potency of SS-14 analogs and unrelated 
peptidee in the inhibition of '2sI-[tyr'1]SS-14 binding to rat 
liver plasma membranes 
IC," Relative 
Peptide (nmol/L) potency 
SS-14 0.55 t 0.07" - 
[TyrolSS-14 1.88 I 0.19 0.29 
[TyrlISS-14 4.09 c 0.48 0.13 
[Tyr"ISS-14 1.00 i 0.09 0.55 
[phe41SS- 14 0.70 2 0.08 0.79 
[D-ti$]ss- 14 0.21 2 0.06 2.62 
SS-28 0.90 t_ 0.12 0.61 
'-"SS-28 5 0.001 - 
IC,, = 50% inhibitory capacity. 
The relative potency of analogs or unrelated peptides (compared 
with SS-14 taken as unity) was calculated from the concentration of 
each peptide required to produce half-maximal inhibition of lZ5I- 
[tyr"lSS-14 binding to membranes. 
"Binding data are expressed as mean -t S.E.M. (n 2 3).  
(Fig. 1B). The presence of 0.5 mmol/L CaC1, was found 
to be necessary because no specific binding was observed 
in the absence of calcium (data not shown). Increasing 
concentrations of synthetic SS-14 inhibited the binding 
of 1261-[tyr11]SS-14 to the liver plasma membranes and 
resulted in a characteristic competition binding profile 
(Fig. 2). This binding data was transformed into a 
Scatchard plot indicating the presence of a single class of 
high-afhity binding sites with an affinity constant (K,) 
of 2.4 k 0.2 nmoUL and a binding capacity (Bmm) of 
148 k 0.02 fmoVmg protein (Fig. 2, inset). 
The specific binding of 1251-[tyr111SS-14 to rat liver 
plasma membranes was further investigated with 
several synthetic analogs of SS-14. The biologically 





FIG. 2. Displacement of 1251-[tyr1 'ISS-14 by increasing concentra- 
tions of SS-14. Rat liver plasma membranes (20 pg/ml) and 
Ityr"1SS-14 (50 pmoVL) were incubated with increasing concentra- 
tions of unlabeled SS-14 at  24" C. Points represent averages of five 
experiments. The Scatchard plot of the binding data is shown in the 
inset. The maximum binding capacity (B,,,=) was calculated as the 
intercept on the abscissa; the afiinity constant (KJ was determined 
from the slope of the line (r = 0.96). Error bars = S.E.M. 
active analog [D-trps]SS-14 was the most potent in 
inhibiting 1251-[tyr111SS-14 binding to the rat liver 
plasma membrane; other analogs - [tyrolSS-14, 
[tyr1]SS-14, [tyr' 'ISS-14 and SS-28 - were compara- 
tively less potent than [D-trpa]SS-14. 1-12SS-28, a so- 
matostatin analog lacking the biologically active portion 
of the molecule, and the unrelated peptides substance P, 
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TABLE 2. Affinity cross-linking of 1aaI-[tyr11]SS-14 to rat 
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FIG. 3. SDS-PAGE of 1261-[tyr11]SS-14 cross-linked to its binding 
protein in rat liver plasma membranes. Liver plasma membranes (50 
pg) were incubated for 50 min at  24" C with 1261-[tyr111SS-14 (150 
pmom). The SS-l4/protein complex was cross-linked with 100 pmolb 
DSS for 15 min. Cross-linked complexes were then subjected to 
SDS-PAGE (12%). Data are representative of three experiments. 
gastrin, motilin and gastrin-releasing peptide were 
unable to displace 1261-[tyr1']SS-14 (Table 1). 
Covalent Cross-linking of 1261-[tyr]11SS-14 to Its 
Binding Protein. To study the biochemical nature and 
molecular weight of the binding protein, 1251- 
[tyP]SS-14 was incubated with the plasma mem- 
branes; the bound complex was then covalently cross- 
linked. One homobifunctional cross-linking reagent, 
DSS, and three heterobifunctional cross-linking 
reagents -HSAB, SAN-PAH and ANB-NOS - were 
used. DSS was found to be the most efficient. Among 
the three heterobifunctional cross-linking reagents, 
ANB-NOS was the most efficient (Table 2). The cross- 
linking efficiency was 1% to 2%, in agreement with the 
work of Susini et al. (15). Autoradiograms from 
SDS-PAGE gels of the cross-linked 1251-[tyr111SS-14 
complexes showed a broad band of radioactivity of mol 
wt 70,000 Da after subtraction of 1,780 Da for the 
calculated molecular weight of 1251-[tyr111SS-14. The 
Reagent cpm ( X  10-9 
DSS (1 mmolL) 
HSAB (0.1 mmolL) 
SAN-PAH (0.1 mmolL) 
ANB-NOS (0.1 mmoVL) 
46.50 rt 3.55" 
8.74 r 0.61 
8.63 2 0.41 
10.58 * 0.58 
Membranes (50 hg) were incubated with 1251-[tyr111SS-14 (150 
p m o a )  for 50 min at 24" C and cross-linked with one of four reagents 
in the concentration noted. Binding and cross-linking with reagents 
were performed as described in "Materials and Methods" (at least four 
experiments per reagent). 
"Data expressed as mean 2 S.E.M. 
TABLE 3. Solubility of cross-linked '2sI-[tyr'11SS-14 to rat 
liver plasma membrane complexes in 
nonreducing detergents 
CPM 
Detergent ( x 10-3, mean f SEM) 
Zwittergent 3-12 1.10 2 0.26" 
CHAPS 0.97 ? 0.17 
Digitonin c 0.02 
Triton X-100 c 0.02 
Rat liver plasma membranes (50 pg) were incubated with 12'1- 
[tyr"]SS-ll (150 pmom), cross-linked with DSS (100 KmolL) and 
solubilized at  a concentration of 1 mg/ml with 1% detergent for 2 hr 
at 4" C. After centrifugation, the supernatant was aspirated, and 
radioactivity was quantitated (at least four experiments per reagent). 
Data expressed as mean * S.E.M. 
presence of this band was eliminated by the addition of 
10 pmolL SS-14 during cross-linking (Fig. 3). Addition 
of 50 mmoVL DTT did not alter the position or number 
of protein bands at mol wt 70,000 Da (Fig. 3) .  
Solubilization of Cross-linked Binding Protein Com- 
plexes in Nondemturing Detergents. To further char- 
acterize the SS-14 binding protein, it was necessary to 
solubilize the labeled complex in nondenaturing deter- 
gents. To investigate the solubility of the binding 
protein, 1% solutions of four detergents (Zwittergent 
3-12, CHAPS, digitonin and Triton X-100) were used. 
Specific binding sites were saturated with '"I- 
[tyrl1]SS-14 (150 pmol/L) and then cross-linked with 
DSS. Increased labeling was not associated with in- 
creased nonspecific binding. Of the four detergents used, 
Zwittergent 3-12 and CHAPS were associated with 
essentially complete solubilization of the labeled com- 
plexes (Table 3). 
Binding of Cross-linked Complexes to WGA-Agarose 
Chromatography Columns. To ascertain whether the 
cross-linked labeled protein was glycosylated, we used 
WGA column chromatography and SDS-PAGE autora- 
diography. DSS cross-linked labeled protein was solubi- 
lized in a 1% solution of Zwittergent 3-12. Solubilized 
complexes were adsorbed on a WGA-agarose column. 
Most of the noncovalently cross-linked radioactivity 
eluted in the first two fractions. After we achieved a 
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FIG. 4. Chromatography of affinity-labeled SS-14 binding proteins 
on WGA-agarose. Fifty micrograms of liver plasma membranes were 
incubated with 1261-[tyr"]SS-14 (150 pmolb), cross-linked with 100 
*mom DSS for 15 min and solubilized with 1% Zwittergent 3-12 (for 
details, see Fig. 3 legend and "Materials and Methods"). Fifty 
micrograms of protein was applied to a WGA f i n i t y  column. The 
column waa washed until no residual activity was noted in the eluate. 
Bound protein was then eluted with 4 mmoVL N, N', N triacetylchi- 
totriose (TACT) as described. Fractions (2.0 ml) were collected, and 
radioactivity was measured. Data are representative of four experi- 
ments. 
plateau, buffer containing 4 mmol/L N, N', N"- 
triacetylchitotriose was added and an additional radio- 
active peak was eluted (Fig. 4). 
Treatment of DSS cross-linked '251-[tyr"lSS-14 
binding protein complexes with endo F before WGA 
column chromatography resulted in loss of binding (Fig. 
5) .  The decrease in the amount of noncovalent cross- 
linked radioactivity that eluted in the initial two frac- 
tions in the control sample in comparison to Figure 4 
reflects an extra wash with buffer. Although deglyco- 
sylation by endo F of DSS cross-linked 1251-[tyr1'3SS-14 
binding proteins abolished binding to WGA-agarose 
columns, no significant alteration in migration on 
SDS-PAGE autoradiography could be noted (Fig. 6 ) .  
E.ysTeet of Nucle0tid.e~ on the Binding of 1261-[tyr1'lSS- 
14. A well-known characteristic of binding proteins 
documented to be receptors is the demonstration of 
coupling to G proteins and regulation by guanine 
nucleotides (16). We investigated the effects of several 
nucleotides on 1251-[tyr11]SS-14 binding to liver plasma 
membranes (Fig. 7 A,B). The specific binding of 1261- 
[tyr"]SS-14 was inhibited by GTP and GDP with 
approximately equal potency, whereas GMP did not 
inhibit specific binding (Fig. 7A). The addition of 
pyruvate b e  and phosphoenol pyruvate to regen- 
erate GTP from GDP increased the inhibition of 
binding, indicating that the membrane preparation can 
4 rnM TACl 
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FIG. 5. Chromatography of endo-F-treated SS-14 binding proteins 
to WGA agarose. Membranes (10 pg) were labeled with lZ6I- 
[tyr"]SS-14 (30 pmolb), cross-linked with 100 pg DSS for 15 min and 
solubilized in Zwittergent 3-12. Membranes were treated with endo F 
(0) or buffer (0) as described (see "Materials and Methods"). The 
column was washed until it was free of residual radioactivity; then 
4 mmol N, N', N-triacetylchitotriose (TACT) was added as indicated. 
Data are representative of three experiments. 




FIG. 6. SDS-PAGE of 1261-[tyr111SS-14 cross-linked to solubilized, 
endo-F-treated membranes. Liver plasma membranes (50 pg) were 
incubated for 50 min at 24" C with '251-[tyr11]SS-14 (150 pmol/L). The 
SS-l4/protein complex was cross-linked with 100 pmolL DSS. 
Cross-linked complexes were then subjected to hydrolysis by endo F; 
this was followed by SDS-PAGE (12%). Data are representative of four 
experiments. 
hydrolyse GTP. In each experiment, care was taken to 
adjust the pH in an attempt to prevent acidic dissoci- 
ation of 1261-[tyr1'JSS-14 to the membrane protein. 
We further compared the effects of GTP with the 
nonhydrolyzable GTP analog guanosine-5'-0-(3-thio- 
triphosphate) (GTP-yS) and ATP on the binding of 
'261-[tyr111SS-14 to the liver plasma membranes. Liver 
plasma membranes were incubated at 24" C with 
1251-[tyr111SS-14 in the presence of various concentra- 
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FIG. 7. (A) Effect of guanine nucleotides on SS-14 binding to rat liver plasma membranes. Rat liver plasma membranes (20 bg) were incubated 
with '251-[tyr1'lSS-14 (50 pmoUL) for 50 min in the presence of various concentrations of GMP, GDP and GTP and a GTP-regenerating system 
(20 U/ml pyruvate kinase and 10 mmoUL phosphoenolpyruvate). Each point represents the mean of duplicate determinations, and the data are 
representative of three experiments. (B) Effect of GTPyS and ATP on SS-14 binding to rat liver plasma membranes. Rat liver plasma membranes 
(20 p,g) were incubated with '261-[tyr'']SS-14 (50 pmoUL) for 50 min in the presence or absence of increasing concentrations of nucleotides 
(GTPyS, GTP or ATP). Each point represents the mean of duplicate determinations, and the data are representative of three experiments. 
tions of GTP, GTPyS and ATP; again, care was taken to 
adjust the pH. GTP and GTPyS inhibited the binding of 
1251-[tyr11]SS-14 in a dose-dependent manner (Fig. 7B). 
The binding of 1251-[tyr111SS-14 appeared to be specifi- 
cally decreased by guanine nucleotides because 
mom ATP had only an attenuated effect. 
DISCUSSION 
In this study, we demonstrated the presence of specific 
binding sites for iodinated SS-14 on rat liver plasma 
membranes. Specific binding was time dependent, sat- 
urable and reversible. The calculated affmity of 2.4 
n m o n  is similar to that of other sites in the gastrointes- 
tinal tract, specifically the stomach and pancreas (12,16, 
17). Our finding of the need for Ca+ + in the binding 
buffer for iodinated SS-14 to specifically bind to liver 
plasma membranes is in agreement with that reported 
for SS-14 binding to its receptor on pancreatic plasma 
membranes (16, 17) and for cyclosomatostatin binding 
to the hepatocytes (9). Sat0 et al. (10) used Krebs-Ringer 
bicarbonate buffer containing glucose and BSA without 
calcium salts; they observed no specific SS-14 binding to 
the liver cell surface (10). This data further emphasizes 
the necessity of Ca+ + in any binding assay buffer. 
In isolated rat liver, it has been shown that 27% of 
SS-28 is converted to SS-14 (21). Conlon et al. observed 
less than 10% degradation of 1251-[tyr11]SS-14 when it 
was exposed to hepatocytes in uitro (22). In this study, 
we used 20 pg of the membranes at 24" C and have 
recovered 92% of the radioactivity as intact tracer as 
measured by Sephadex G-50 column chromatography. 
Taken together, the data suggest that isolated mem- 
branes are the best available model for the study of liver 
membrane SS-14 binding proteins (12, 15-17). 
Displacement of 1251-[tyr1']SS-14 with biologically 
active somatostatin analogs, but not by biologically 
inactive l-12SS-28 or other unrelated peptides, was 
demonstrated (Table 1). Because SS-14 is thought to 
be the physiological ligand for the SS-14 receptor, the 
ability of SS-14 analogs to displace 1251-[tyr'11SS-14 
was judged with SS-14 as the standard. Interestingly, 
[tyrl1]SS-14 and other tyrosinylated analogs were 
less capable of displacement of radioligand than was 
SS-14. SS-14 analogs modified in the ring portion of 
the molecule-especially at position 8, such as 
D-trp'-were more potent in displacing SS-14, in ac- 
cordance with data reported in pancreatic acinar mem- 
branes (16). The relative potency of each analog in 
inhibiting binding of 1261-[tyr1'lSS-14 to liver plasma 
membranes also correlated with known biological po- 
tency (Table 2; 16, 17, 21). The data support the 
contention that binding of '251-[tyr111SS-14 to liver 
plasma membranes is specific. 
To further characterize the nature of the SS-14 
binding sites, 1251-[tyr11]SS-14 was cross-linked to 
binding sites on the rat liver plasma membranes with 
one homobifunctional and three heterobifunctional 
cross-linking reagents, as described previously, to study 
peptide hormone receptors (15, 16). Of the four cross- 
linking reagents used, the homobifunctional reagent 
DSS was found to be the most efficient. The data are 
similar to that found for SS-14 binding in pancreas (16). 
Our finding of a labeled band at mol wt 70,000 Da 
suggests that the binding site is a protein of 70,000 Da 
and similar to that reported by Ogawa (8). Complete 
absence of this band in the presence of 10 FmoVL SS-14 
further confirms the saturability of the binding (Fig. 3). 
Identification of the band in the same position in 
presence of the reducing agent DTT also suggests that 
the SS-14 binding protein does not contain sulfhydryl 
linkages or subunits (15). The meaning of observed 
variations in the reported size of SS-14 receptors is 
unknown; however, the finding of an SS-14 binding 
protein with an approximate mol wt 70,000 Da in this 
study, one of 92,000 Da in pancreas (17) and another of 
60,000 Da in brain (23) could be due to alternative 
messenger RNA processing or posttranslational pro- 
cessing of a common protein (24, 25). Such molecular 
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variations might explain functional differences in SS- 14 
receptor subtypes (26, 27). 
The band of cross-linked radloactivity is somewhat 
broad (Fig. 3) and suggests that it is a glycoprotein (28). 
To further investigate the possibility that sugar moieties 
were present, the cross-linked, radiolabeled binding 
protein was first solubilized in nondenaturing deter- 
gents. Zwittergent 3-12 and CHAPS were most efficient, 
similar to findings in pancreatic and brain membranes 
(15, 23). Adsorption of the cross-linked SS-14 binding 
protein by WGA-agarose columns and elution by a 
competing sugar, N, N’ , N”-triacetylchitotriose (Fig. 41, 
suggest that the cross-linked SS- 14 binding protein is 
indeed a glycoprotein and supports previous observa- 
tions that a broad band on SDS-PAGE is an indication 
of the presence of glycosylation (28). No increased 
migration of the radioactive band is seen on SDS-PAGE, 
despite the loss of binding to WGA columns after endo F 
treatment of DSS cross-linked 1251-[tyr1 ‘ISS-14 binding 
proteins, suggesting that the SS-14 binding protein is 
only sparsely glycosylated with mannose oligosaccha- 
rides to a degree not resolvable by PAGE (18). 
In summary, we showed that the specific binding of 
1251-[tyr11]SS-14 to liver plasma membranes is inhibited 
by the presence of GMP, GDP, GTP and GTP with 
pyruvate kinase (Fig. 7A), suggesting regulation by 
guanine nucleotide binding proteins (G proteins). The 
data support the hypothesis that G proteins may 
mediate SS-14-inhibited cyclic AMP synthesis in hepa- 
tocytes (4). The potential interaction of the 1251- 
[tyr1’lSS-14 binding protein with G proteins is further 
supported by the observation of increasing inhibition of 
binding of 1261-[tyr1’]SS-14 to liver plasma membranes 
in the presence of GTPyS (Fig. 7B). The demonstration 
of a SS-14-specific, saturable, hepatocyte membrane 
binding protein; the biochemical characteristics; and the 
inhibition of binding by guanine nucleotides all suggest 
that this protein functions as a hepatic SS-14 receptor. 
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